| Date Filed | Type | Description |
| 08/10/2023 |
SC 13G/A
| FMR LLC reports a 0% stake in THESEUS PHARMACEUTICALS INC |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
4
| GORDON CARL L (10% Owner) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Bought 328,482 shares
@ $3.05, valued at
$1M
Bought 151,450 shares
@ $3.05, valued at
$461.9k
|
|
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/19/2023 |
4
| Foresite Capital Management V, LLC (10% Owner) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Bought 523,450 shares
@ $2.97, valued at
$1.6M
Bought 176,550 shares
@ $2.97, valued at
$524.4k
|
|
| 07/19/2023 |
SC 13D/A
| Foresite Capital Fund V, L.P. reports a 12.6% stake in Theseus Pharmaceuticals, Inc. |
| 07/13/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ... |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/25/2023 |
8-K
| Investor presentation |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/14/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 39.6% stake in Theseus Pharmaceuticals, Inc. |
| 03/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Quarterly results |
| 03/02/2023 |
4
| Rivera Victor (Chief Scientific Officer) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Granted 16,250 restricted stock units
@ $0 |
|
| 03/02/2023 |
4
| Shakespeare William (See Remarks) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Granted 21,250 restricted stock units
@ $0 |
|
| 03/02/2023 |
4
| Kerstein David (Chief Medical Officer) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 restricted stock units
@ $0 |
|
| 03/02/2023 |
4
| Dahms Bradford D. (CFO) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 restricted stock units
@ $0 |
|
| 03/02/2023 |
4
| CLACKSON TIMOTHY P (President and CEO) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Granted 45,625 restricted stock units
@ $0 |
|
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/23/2023 |
SC 13G
| Frazier Life Sciences Public Fund, L.P. reports a 5.8% stake in Theseus Pharmaceuticals, Inc. |
| 01/05/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...|
Docs:
|
"Legal notice and forward - looking statements 2 ©2023 Theseus Pharmaceuticals. Certain statements included in this presentation are not historical facts but are forward - looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward - looking statements generally are accompanied by words such as "believe ," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," “on track,” "predict," "potential," "seem," "seek," "future," "o utl ook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a st atement is not forward - looking. The...",
"Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL" |
|
| 01/03/2023 |
SC 13D/A
| Foresite Capital Fund V, L.P. reports a 12.4% stake in Theseus Pharmaceuticals, Inc. |
| 01/03/2023 |
4
| Foresite Capital Management V, LLC (10% Owner) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Bought 250,000 shares
@ $5, valued at
$1.3M
Bought 250,000 shares
@ $5, valued at
$1.3M
|
|
| 01/03/2023 |
4
| HAYDEN DONALD J JR (Director) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Bought 100 shares
@ $5, valued at
$500
Bought 9,900 shares
@ $4.9989, valued at
$49.5k
|
|
| 12/01/2022 |
4
| Dahms Bradford D. (CFO) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Bought 1,502 shares
@ $6.657, valued at
$10k
|
|
| 11/09/2022 |
4
| GORDON CARL L (10% Owner) has filed a Form 4 on Theseus Pharmaceuticals, Inc.|
Txns:
| Bought 192,000 shares
@ $5.21, valued at
$1M
|
|
|